key: cord-0803220-jsoenr9g
authors: Danwang, Celestin; Endomba, Francky Teddy; Nkeck, Jan René; Wouna, Dominic Leandry Angong; Robert, Annie; Noubiap, Jean Jacques
title: A meta-analysis of potential biomarkers associated with severity of coronavirus disease 2019 (COVID-19)
date: 2020-08-31
journal: Biomark Res
DOI: 10.1186/s40364-020-00217-0
sha: f0de59177411547f310c2a68ab3e1140466ec404
doc_id: 803220
cord_uid: jsoenr9g

BACKGROUND: Prognostic factors for the Coronavirus disease 2019 (COVID1–9) are not well established. This study aimed to summarize the available data on the association between the severity of COVID-19 and common hematological, inflammatory and biochemical parameters. METHODS: EMBASE, MEDLINE, Web of sciences were searched to identify all published studies providing relevant data. Random-effects meta-analysis was used to pool effect sizes. RESULTS: The bibliographic search yielded 287 citations, 31 of which were finally retained. Meta-analysis of standardized mean difference (SMD) between severe and non-severe COVID-19 cases showed that CK-MB (SMD = 0.68,95%CI: 0.48;0.87; P-value:< 0.001), troponin I (SMD = 0.71, 95%CI:0.42;1.00; P-value:< 0.001), D-dimer (SMD = 0.54,95%CI:0.31;0.77; P-value:< 0.001), prothrombin time (SMD = 0.48, 95%CI:0.23;0.73; P-value: < 0.001), procalcitonin (SMD = 0.72, 95%CI: 0.34;1,11; P-value:< 0.001), interleukin-6 (SMD = 0.93, 95%CI: 0.25;1.61;P-value: 0.007),C-reactive protein (CRP) (SMD = 1.34, 95%CI:0.83;1.86; P-value:< 0.001), ALAT (SMD = 0.53, 95%CI: 0.34;0,71; P-value:< 0.001), ASAT (SMD = 0.96, 95%CI: 0.58;1.34; P-value: < 0.001), LDH (SMD = 1.36, 95%CI: 0.75;1.98; P-value:< 0.001), CK (SMD = 0.48, 95%CI: 0.10;0.87; P-value:0.01), total bilirubin (SMD = 0.32, 95%CI: 0.18;0.47;P-value: < 0.001), γ-GT (SMD = 1.03, 95%CI: 0.83;1.22; P-value: < 0.001), myoglobin (SMD = 1.14, 95%CI: 0.81;1.47; P-value:< 0.001), blood urea nitrogen (SMD = 0.32, 95%CI: 0.18;0.47;P-value:< 0.001) and Creatininemia (SMD = 0.18, 95%CI: 0.01;0.35; P-value:0.04) were significantly more elevated in severe cases, in opposition to lymphocyte count (SMD = -0.57, 95%CI:-0.71; − 0.42; P-value: < 0.001) and proportion of lymphocytes (SMD = -0.81, 95%CI: − 1.12; − 0.49; P-value:< 0.001) which were found to be significantly lower in severe patients with other biomarker such as thrombocytes (SMD = -0.26, 95%CI: − 0.48; − 0.04; P-value:0.02), eosinophils (SMD = − 0.28, 95%CI:-0.50; − 0.06; P-value:0.01), haemoglobin (SMD = -0.20, 95%CI: − 0.37,-0.03; P-value:0.02), albuminemia (SMD-1.67,95%CI -2.40; − 0.94; P-value:< 0.001), which were also lower. Furthermore, severe COVID-19 cases had a higher risk to have lymphopenia (RR =1.66, 95%CI: 1.26;2.20; P-value:0.002), thrombocytopenia (RR = 1.86, 95%CI: 1.59;2.17; P-value: < 0.001), elevated procalcitonin level (RR = 2.94, 95%CI: 2.09–4.15; P-value:< 0.001), CRP (RR =1.41,95%CI: 1.17–1.70; P-value:0.003), ASAT(RR =2.27, 95%CI: 1.76;2.94; P-value:< 0.001), CK(RR = 2.61, 95%CI: 1.35;5.05; P-value: 0.01), Creatininemia (RR = 3.66, 95%CI: 1.53;8.81; P-value: 0.02) and LDH blood level (RR = 2.03, 95%CI: 1.42;290; P-value: 0.003). CONCLUSION: Some inflammatory (procalcitonin, CRP), haematologic (lymphocyte, Thrombocytes), and biochemical (CK-MB, Troponin I, D-dimer, ASAT, ALAT, LDH, γ-GT) biomarkers are significantly associated with severe COVID-19. These biomarkers might help in prognostic risk stratification of patients with COVID-19.

Coronavirus disease 2019 (COVID-19) which emerged in Wuhan, China, has spread to almost all countries and regions of the world, becoming one of the most lethal pandemic after the Spanish flu in 1918-1920. It is caused by an RNA virus (2019 novel coronavirus or 2019-nCoV or SARS-CoV-2). As of July 13, 2020, a total of 12,768,307 confirmed COVID-19 cases and 566,654 related deaths have been reported [1] . Beyond its important morbidity and mortality and the huge burden of health care systems, COVID-19 has a massive societal and economic impact globally.

To date, there is no established curative treatment for COVID- 19 . Although some drugs such as hydroxychloroquine are integrated in treatment guidelines or under investigation in interventional studies, the management of COVID-19 is mostly supportive. [2] [3] [4] Identifying biological abnormalities induced by COVID-19 may contribute to a better understanding of the pathophysiology of the disease and ultimately guide the development of targeted adjuvant therapies besides antivirals drugs. Furthermore, such information on the biological profile of COVID-19 can guide clinicians in the assessment and treatment of these patients.

Clinically, most of COVID-19 cases (80%) are either asymptomatic or have mild forms. [4, 5] However, about 13.8 and 6.1% have severe and critical life-threatening disease that require admission to hospital and sometimes in the intensive care unit. [5] In the context of outstretched heath care systems and limited resources, risk stratification is pivotal to identify patients who the most need in-hospital and intensive management. Biomarkers along with some clinical factors might help to predict adverse outcomes among COVID-19 patients. Hence, we conducted this systematic review and meta-analysis to summarize available data on the association between some common hematological, inflammatory, biochemical parameters and the severity of COVID-19.

This review is reported according to the MOOSE (Metaanalysis Of Observational Studies in Epidemiology) guidelines [6] .

We searched PubMed, EMBASE and Web of sciences from inception to April 18, 2020 , to identify studies in English or French reporting biological work-up results in patients with biologically confirmed (with polymerase chain reaction assays) COVID-19. The search strategies are presented in the appendix (Supplementary Table 1 and 2). Furthermore, the reference list of eligible studies was analysed to identify potential additional data sources. For duplicates publications or studies conducted on the same group of patients, the study with the largest sample size was considered. We excluded studies from which we could not obtain data on the prevalence of abnormalities or the mean and standard deviation (or median and interquartile range) of the reported biomarker in severe and non-severe patients.

Two investigators (CD and FTE) independently assessed the articles retrieved from the literature search to determine their potential eligibility based on titles and abstracts. The full texts of selected articles were then downloaded and assessed for final inclusion. Discrepancies were resolved by discussion and consensus.

An electronic data abstraction form was used by four investigators (CD, FTE, JRN and DLAW) to extracted relevant information in accordance with the objectives of the review. One investigator (JJN) crosscheck extracted data. For each study data extracted included: surname of the first author, year of publication, country and city where the study was conducted, study design, timing of data collection, sample size, proportion of males, study sample size, biological abnormalities reported, mean and standard deviation (or median and interquartile range) of reported biomarkers.

All patients presenting blood oxygen saturation ≤ 93%; respiratory failure; septic shock; multiple organ dysfunction; dyspnea;respiratory rate greater than 30/min, PaO2/ FiO2 ratio < 300, and/or lung infiltrates > 50% of the lung field within 24-48 h were considered as severe cases as recommended by the World Health Organization. [5] Data synthesis and analysis A DerSimonian and Laird random-effects meta-analysis model was used to obtain the pooled effect size within the statistical software R (version 3.6.2). For studies reporting median and interquartile range of the biomarker, only those with a reported number of cases greater than 25 were included in the standardized mean difference (SMD) meta-analysis. Prior to pooling effect sizes, the standard deviation of each mean value was computed from the interquartile range by taking the difference between Q3 and Q1 and dividing by 1.35 as recommended in the Cochrane handbook of systematic review [7] . Pooled OR and SMD of each biomarker are reported with their 95% confidence intervals.

Cochran's χ 2 and the I 2 tests were used respectively to assess the presence and the amount of heterogeneity, with the cut-off of I 2 values of 25, 50 and 75% representing low, medium and high heterogeneity respectively [8, 9] . Publication bias was assess by the inspection of the Funnel plot and the Egger test (p < 0.10) [10] . Unless otherwise specify, a p value < 0.05 was considered as statistically significant for all analysis.

The bibliographical search yielded 287 eligible articles, of which 31 were finally retained for the systematic review, and 16 for the meta-analysis as depicted in the study selection process (Supplementary Figure 1) . Two studies were conducted in Singapore [11, 12] and all the others in China in 2020 (Table 1 ). Twelve of the included studies were conducted in Wuhan. Twentyeight studies had collected data retrospectively while three were prospective. All included studies except one (which was cross sectional) were case series with patients having a mean age ranging from 9 to 70.5 years in severe cases and from 7.5 to 59.7 years in non-severe cases. The proportion of males ranged from between 40.7 and 73%. Three studies reported data on survivors and non-survivors (Table 1) . (Table 4 ). More details on the metaanalysis and forest plots are available in the appendix (Supplementary file).

There was a significant difference in D-dimer and prothrombin time (PT) between severe and non-severe cases, with severe cases having a higher D-dimer level (SMD = 0.54,95%CI:0.31;0.77; P-value: < 0.001; n = 1583) and prothrombin time (SMD = 0.48, 95%CI:0.23;0.73; Pvalue: < 0.001; n = 357).

Troponin I blood level were significantly higher in severe patients (SMD = 0.71, 95%CI: 0.42;1.00; P-value:< 0.001; n = 430) as well as CK-MB levels (SMD = 0.68,95%CI: 0.48;0.87; P-value:< 0.001; n = 1150), and this was consistent across all studies included in the meta-analysis of the above-mentioned biomarkers ( Table 2) .

Severe COVID-19 cases had significantly higher blood level of procalcitonin (SMD = 0.72, 95%CI: 0.34;1,11; Pvalue: < 0.001; n = 1509), interleukin-6 (SMD = 0.93, 95%CI: 0.25;1.61; P-value: 0.007; n = 875),and C-reactive protein (SMD = 1.34, 95%CI:0.83;1.86; P-value: < 0.001; n = 1974) ( Table 2) . Moreover, IL-6 was significantly higher in non-survivor compare to survivor cases (SMD = 1.23, 95%CI: 0.77;1.68; P-value:< 0.001; n = 275).

Severe cases were more likely to have a higher procalcitonin level (RR =2.94, 95%CI: 2.09; 4.15; P-value: < 0.001; n = 1262), and CRP (RR =1.41,95%CI: 1.17; 1.70; P-value: 0.003; n = 1349) ( Table 4) .

Overall, severe COVID-19 cases were found to have (Table 3 ).

This review shows that patients with a severe form of COVID-19 have higher level of CK-MB,troponin I, D-dimer, prothrombin time, procalcitonin, interleukin-6, C-reactive protein, ALAT, ASAT, LDH, CK, total bilirubin, γ-GT, myoglobin, blood urea nitrogen, creatininemia and lower level of lymphocyte, thrombocytes, eosinophils, haemoglobin and albuminemia.

It has been shown that COVID-19 infection is associated with a severe systemic immune response drive by a "cytokine storm". [42] [43] [44] Our data point to an association between procalcitonin (PCT), CRP levels and the severity of the disease. This is supported by previous findings which has reported elevated levels of several pro inflammatory cytokines including IL-2, IL-6, IL-7, MCP1, and TNF alpha, which contributes to increase classical inflammatory biomarkers such as PCT and CRP and are found to be higher in the severe forms of the disease. [42, 43, 45] Mechanistically, it has been show that, after the virus entry in the pneumocytes via the ACE2 receptor, it triggers a systemic inflammatory response, creating an immune dysfunction with a hyperactivity of T lymphocytes and the release of pro inflammatory cytokines mentioned above. [42, 43, 46] If the inflammation is initially protective, it appears secondarily that most cellular and tissue lesions are more the result of hyperinflammation than of the direct effect of the virus. [42, 43] These two phenomena may favor at the respiratory level, pulmonary lesions, by hypercapillary permeability and pulmonary edema, leading to acute respiratory distress. [42, 47] OR odd ratio; CRP C-reactive protein; CK Creatine kinase; IL-6 interleukin-6; ALAT alanine amino-transferase; ASAT aspartate amino-transferase; LDH Lactate dehydrogenese Thus for clinicians, the measurement of classical and accessible inflammatory markers namely PCT and CRP, may help assessing the hyper inflammatory activity, and thus the severity of cases of severe infections. Furthermore, the use of therapies targeting inflammation to reduce the deleterious effects of the cytokine storm appear to be necessary. In this line, some studies have reported the beneficial effects of immunosuppressive and immunomodulatory therapies. [50] [51] [52] However, the benefit of the use of corticosteroids and non-steroidal anti-inflammatory drugs to reduce hyperinflammation during the 2019-nCoV infection is still controversial. [39] [40] [41] Cardiac biomarkers imbalanced and COVID-19

Our analysis revealed that severe COVID-19 cases have elevated levels of biomarkers of cardiomyocytes injury such as Troponin I, CK-MB, CK and myoglobin. Numerous previous researches have reported a cardiac involvement in patients with 2019-nCoV. [53] [54] [55] [56] In a recently published study, Lippi and colleagues reported that the values of cardiac Troponin I were significantly increased in COVID-19 cases with severe disease than in those without. [55] Notwithstanding the incomplete knowledge on its pathophysiology, the mainly suggested mechanisms are: myocardial ischemia due to increased oxygen demand but in the context of hypoxemia and plaque disruption triggered by cytokine storm; these two being most frequently encountered among patients with coronary artery disease. [57] [58] [59] [60] Also, myocardial inflammation, which can be the result of systemic immune response is another mechanism of heart injury among COVID-19 cases. [61, 62] Likewise, it has been hypothesised a direct viral toxicity through the interaction with ACE2 receptors highly expressed by some pericytes. [59] A thorough cardiac assessment should therefore be conducted in the follow-up of severe COVID-19 cases and manage properly to avoid adverse outcome.

Hematological changes encountered in the course of the novel coronavirus infection are common and concern mainly white blood cells and platelets. [63] In our study, some keys parameters modifications, notably lymphopenia and thrombocytopenia, are associated with severe form of the disease. [64] Indeed, we found decreased overall mean levels of lymphocyte count among severe 2019-nCoV patients. Moreover, patients with severe 2019-nCoV infection were more likely to have lymphopenia. Low lymphocyte count has also been reported for other viral respiratory infection such as the one due to Respiratory Syncytial Virus (RSV). [65] This immune response marked by a profound lymphopenia seem to be is delay complication that come after an early massive release of cytokine during the course of the SRAS-Cov-2 lung injury. [66] [67] [68] The effects of COVID-19 on lymphocytes can be explained by direct and/or indirect mechanisms. The direct insult could be related to 2019-nCoV cytotoxicity, sustained by active viral replication within pool of infected lymphocytes. [67, 69] However, angiotensin-converting enzyme 2 (ACE2) has been identified as a functional cellular receptor for the COVID-19, a protein that is not expressed on circulating B or T lymphocytes. [66, 70] Studies suggested a potential role of alveolar macrophages which can promote viral entry via antigen presentation to T lymphocytes. [66, 67] Indirect lymphocytes damage could appear through huge cytokines release which can induce cells apoptosis. [66, 68, 69] In addition, high glucocorticoids levels induced by severe 2019-nCov can pertain to the down regulation of proinflammatory lymphokine ultimately lead to the lymphocyte activation and proliferation alteration . [67, 68] . [71] Clinicians should therefore keep in mind that severe cases of COVID-19 have depressed lymphocyte levels and are therefore more prone to infection.

Another key hematological disturbance found in our review was thrombocytopenia. Indeed, our analysis revealed significantly reduced mean platelets count in cases with severe COVID-19. Moreover, patients with severe form of the disease were more likely to have low platelets counts. Some potential mechanisms of SRASassociated thrombocytopenia have been proposed. Coronavirus can infect bone marrow cells and thereby reduce platelet production. [72] Indeed some strains of coronavirus like HCoV-229 have their receptor on humans cells like those of kidney, lung and platelets, named Human amino peptidase N (CD13). [73] 2019-nCoV infection may also increase peripheral destruction of platelet [72, 74] by immunological mechanism by generating auto antibodies and immune complex. [75] Similar response have been reported for other viruses like HIV 1 in which Anti-platelet membrane GPIIIa49-66 IgG antibodies can cross-react with the HIV-1GP 160/ 120 antigen. [75] Other pathways can be the consumption of platelet following severe lung inflammation result in platelets activation and formation of microthrombi. [72] Thrombocytopenia, which makes cases with severe forms of the disease susceptible to primary coagulation impairment, is therefore an important element to consider and address in the daily management and evaluation of these patients.

Four main coagulation biomarkers disturbances were found in severe COVID-19 cases namely higher serum D-dimers, longer prothrombin time (PT), and lower platelets counts. Moreover, we found that patients with severe 2019-nCoV infection are more likely to have increase serum D-dimers.

Coronavirus disease 2019 can affect haemostasis and blood coagulation in many ways, both regarding abnormal bleeding risk and thromboembolism. [72, [76] [77] [78] [79] In addition to thrombocytopenia mechanistic hypotheses stated earlier, it must be suggest the potential implication of COVID-19 liver injury an aetiological element of haemostasis disorder though the impaired production of coagulation factors. [72, 76, 77] Concerning D-dimers, increased levels might be the result of the sepsis-induced disseminated intravascular coagulation and reflect thromboembolic risk in severe COVID-19 cases. [80] [81] [82] There are mounting evidences supporting the key pathological role of thromboembolic processes in SARS-CoV-2 disease and severity. [83] [84] [85] [86] Due to the low specificity of this biomarker, its results in Covid-19 patients should be interpreted in the context of other associated conditions that may also potentially increase D-dimer levels.

Decreased platelet counts and increased prothrombin time in patients with covid-19 are probably due to consumption coagulopathy. The latter occurs as a result of an abnormal increase in the activation of procoagulant pathways which induces a decrease in plasma concentrations of fibrinogen, platelets and other clotting factors. [87] A daily assessment of the coagulation profile of cases with severe forms of the disease appears vital and the correction of those abnormalities unavoidable to improve the prognosis. Cases of COVID-19 with bloodclotting abnormalities should be managed very closely and invasive treatments that may lead to bleeding should be avoided.

Numerous liver biomarkers abnormalities have been described as being associated with COVID-19 encompassing increased levels of total bilirubin, transaminases, γ-GT, LDH, and low albumin levels. [88] [89] [90] [91] Our results revealed that some of these biomarkers (ASAT/ALAT, γ-GT, LDH) have a significantly higher level in severe cases, and that severe cases are more likely to have high levels of ASAT and LDH.

It has been reported a virus-induced cytopathic effect notably through the binding with the ACE2 receptor for its target cells entry. [91, 92] Another potential triggering factor of detrimental liver consequences is immunemediated inflammation in parallel with the "cytokine storm". [76, 93, 94] Moreover, the immune responses ensured by B and T cells lymphocytes can also sustain this inflammation. [67, 68] It has also been put forward stress on sepsis related ischemic/hypoxic liver injury as putative mechanisms of abnormal hepatic function. [95, 96] Hepatic sinuses congestion related to thrombosis and/or high levels of positive end expiratory pressure can also be a contributing explanatory mechanisms of liver damage. [93, 95, 97] Likewise, COVID-19 patients may experience drug-induced liver injury (DILI), [93, 98] and reactivation of pre-existing hepatic conditions (going from viral hepatitis to liver cirrhosis). [90, 97, 99] Therefore, drugs which are known to be hepatotoxic or which are metabolized by the liver should be administered with caution or should be avoided in severe cases. Nevertheless, the results of liver biomarkers in COVID-19 cases must be interpreted in the context of the presence of other comorbidities that may induce an increase in these biomarkers.

Our findings point to an overall higher levels of urea nitrogen and creatinine among COVID-19 severe cases. Further studies are needed to better understand renal involvement in severe COVID-19 cases, especially since some pathophysiological hypotheses suggest the possibility of kidney damages related to COVID-19 infection. [100] [101] [102] [103] The current research provides evidence-based elements that can help clinicians in decision making when dealing with COVID-19 cases. Future studies should explore novel biomarkers, such as non-coding RNAs or proteomics, for disease progression and severity of COVID-19 and similar diseases in order to build powerful prediction tools.

The results of the current review should be interpreted in the context of some limitations. Firstly, it was not possible to assess the dynamic of biomarkers and to determine whether the samples were taken on admission or later during hospitalization. Therefore, the kinetic of biomarkers during the disease progression to severity cannot be established. Secondly, all the studies included in the meta-analysis were from China. Different biological patterns might be observed across populations from various geographical and ethnic background. Therefore, this limits the generalizability of our findings and call to more research on the topic in population from different countries and ethnicities. Thirdly, the measurement of biomarkers was probably different between studies, with various devices and diagnostic reference values. However, in most studies, there was low to moderate heterogeneity, suggesting that observations were consistent across studies. Nevertheless, this study is one of the first to analyse potential biomarkers associated with the severity of 2019-nCoV infection. We used state-of-the-art statistical methods in order to derive the most accurate estimates.

Some inflammatory (procalcitonin, CRP), haematologic (lymphocyte, Thrombocytes), and biochemical (CK-MB, Troponin I, D-dimer, ASAT, ALAT, LDH, γ-GT) biomarkers are significantly associated with severe COVID-19. These biomarkers might help in prognostic risk stratification of patients with COVID-19. Our findings could also contribute in the establishment of an accurate and reproducible COVID-19 biological severity score.

Supplementary information accompanies this paper at https://doi.org/10. 1186/s40364-020-00217-0. Figure 1 . The review process.

COVID-19) -World Health Organization

The proportion of patients with thrombocytopenia in three human-susceptible coronavirus infections: a systematic review and meta-analysis

Evaluation and Treatment Coronavirus (COVID-19)

Mild or Moderate Covid-19

Report of the WHO-China Joint Mission on Coronavirus Disease

Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis of observational studies in epidemiology (MOOSE) group

Cochrane Handbook for Systematic Reviews of Interventions

Available from: www.training.cochrane.org/handbook

Assessing heterogeneity in meta-analysis: Q statistic or I2 index?

The combination of estimates from different experiments

Bias in meta-analysis detected by a simple, graphical test

Hematologic parameters in patients with COVID-19 infection

Epidemiologic features and clinical course of patients infected with SARS-CoV-2 in Singapore

Characteristics of liver tests in COVID-19 patients

COVID-19 in a designated infectious diseases hospital outside Hubei Province

Neurologic Manifestations of Hospitalized Patients With Coronavirus Disease

Epidemiological and clinical features of 125 hospitalized patients with COVID-19 in

COVID-19 with different severity: a multi-center study of clinical features

Clinical features and treatment of COVID-19 patients in Northeast Chongqing

Clinical features of 69 cases with coronavirus disease 2019 in Wuhan, China

Clinical and computed tomographic imaging features of novel coronavirus pneumonia caused by SARS-CoV-2

Differences between COVID-19 and suspected then confirmed SARS-CoV-2-negative pneumonia: a retrospective study from a single center

Clinical and transmission characteristics of Covid-19 -a retrospective study of 25 cases from a single thoracic surgery department

Clinical and immunological features of severe and moderate coronavirus disease 2019

The clinical and chest CT features associated with severe and critical COVID-19 pneumonia

Clinical features of patients infected with 2019 novel coronavirus in Wuhan

Clinical characteristics of 161 cases of corona virus disease 2019 (COVID-19) in Changsha

Clinical and epidemiological features of 36 children

China: an observational cohort study

Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study

Clinical characteristics of coronavirus disease 2019 in China

Clinical characteristics of 140 patients infected with SARS-CoV-2 in Wuhan

Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan

Prominent changes in blood coagulation of patients with SARS-CoV-2 infection

Risk Factors Associated With Acute Respiratory Distress Syndrome and Death in Patients With Coronavirus Disease

Clinical and biochemical indexes from 2019-nCoV infected patients linked to viral loads and lung injury

Analysis of factors associated with disease outcomes in hospitalized patients with 2019 novel coronavirus disease

Dysregulation of immune response in patients with COVID-19 in Wuhan, China

Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China. Intensive Care Med

Platelet-tolymphocyte ratio is associated with prognosis in patients with coronavirus disease-19

Epidemiologic and Clinical Characteristics of 91 Hospitalized Patients with COVID-19 in Zhejiang, China: A retrospective, multi-centre case series

Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a singlecentered, retrospective, observational study

Clinical analysis on risk factors for COVID-19 patients becoming severe patients

MyBioGate Global COVID-19 Resources Platform

Virology, epidemiology, pathogenesis, and control of COVID-19

The epidemiology and pathogenesis of coronavirus disease (COVID-19) outbreak

The trinity of COVID-19: immunity, inflammation and intervention

COVID-19: immunopathology and its implications for therapy

COVID-19 pathophysiology: A review

COVID-19, cytokines and immunosuppression: what can we learn from severe acute respiratory syndrome?

COVID-19: consider cytokine storm syndromes and immunosuppression

Cytokine release syndrome in severe COVID-19

Cytokine storm and immunomodulatory therapy in COVID-19: role of chloroquine and anti-IL-6 monoclonal antibodies

The cytokine release syndrome (CRS) of severe COVID-19 and Interleukin-6 receptor (IL-6R) antagonist Tocilizumab may be the key to reduce the mortality

Trends in maternal and fetal outcomes among pregnant women with systemic lupus erythematosus in the United States

Cardiac involvement in COVID-19 patients: risk factors, predictors, and complications: a review

Cardiac involvement in a patient with coronavirus disease 2019 (COVID-19)

Sanchis-Gomar F. Cardiac troponin I in patients with coronavirus disease 2019 (COVID-19): evidence from a meta-analysis

Association of cardiac injury with mortality in hospitalized patients with COVID-19 in Wuhan, China

COVID-19 and the heart

COVID-19 for the cardiologist: a current review of the virology, Clinical Epidemiology, Cardiac and Other Clinical Manifestations and Potential Therapeutic Strategies

The ACE2 expression in human heart indicates new potential mechanism of heart injury among patients infected with SARS-CoV-2

COVID-19 and the cardiovascular system

First case of COVID-19 complicated with fulminant myocarditis: a case report and insights

SARS-CoV-2 inflames the heart. The importance of awareness of myocardial injury in COVID-19 patients

Hematologic parameters in patients with COVID-19 infection

Haematological parameters in severe acute respiratory syndrome

Early immune responses accompanying human asymptomatic Ebola infections

SARS-CoV-2 and viral sepsis: observations and hypotheses

Coronavirus infections and immune responses

COVID-19 infection: the perspectives on immune responses

Hematological findings and complications of COVID-19

Tissue distribution of ACE2 protein, the functional receptor for SARS coronavirus. A first step in understanding SARS pathogenesis

Lymphopenia and neutrophilia in SARS are related to the prevailing serum cortisol

Mechanism of thrombocytopenia in COVID-19 patients

Human aminopeptidase N is a receptor for human coronavirus 229E

Platelet-to-lymphocyte ratio is associated with prognosis in patients with coronavirus disease-19

Complement-independent, peroxide-induced antibody lysis of platelets in HIV-1-related immune thrombocytopenia

Liver injury in COVID-19: management and challenges

COVID-19 and thrombotic or thromboembolic disease: implications for prevention, antithrombotic therapy, and follow-up

Changes in blood coagulation in patients with severe coronavirus disease 2019 (COVID-19): a meta-analysis

COVID-19 cytokine storm: the interplay between inflammation and coagulation

Coagulation disorders in coronavirus infected patients: COVID-19, SARS-CoV-1, MERS-CoV and lessons from the past

Disseminated intravascular coagulation in patients with 2019-nCoV pneumonia

Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia

Thromboembolic risk and anticoagulant therapy in COVID-19 patients: emerging evidence and call for action

Incidence of thrombotic complications in critically ill ICU patients with COVID-19

Pathological findings of COVID-19 associated with acute respiratory distress syndrome

A pathological report of three COVID-19 cases by minimally invasive autopsies

Consumption Coagulopathy: Practice essentials

COVID-19 and liver dysfunction: current insights and emergent therapeutic strategies

COVID-19: Abnormal liver function tests

COVID-19 and liver disease

Exploring the mechanism of liver enzyme abnormalities in patients with novel coronavirus-infected pneumonia

The novel coronavirus 2019 (2019-nCoV) uses the SARS-coronavirus receptor ACE2 and the cellular protease TMPRSS2 for entry into target cells

Hepatic and gastrointestinal involvement in coronavirus disease 2019 (COVID-19): what do we know till now?

Dynamic changes in clinical features and cytokine/chemokine responses in SARS patients treated with interferon alfacon-1 plus corticosteroids

Clinical Features of COVID-19-Related Liver Damage

Liver -guardian, modifier and target of sepsis

Characteristics and mechanism of liver injury in 2019 coronavirus disease

COVID-19 and drug-induced liver injury: a problem of plenty or a petty point?

Implications of COVID-19 for patients with pre-existing digestive diseases

Kidney involvement in COVID-19 and rationale for extracorporeal therapies

Human Kidney is a Target for Novel Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection

COVID-19 and the Renin-Angiotensin System

Kidney disease is associated with in-hospital death of patients with COVID-19

Publisher's Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations

None.

Availability of data and materials All related materials are available in the appendix.Ethics approval and consent to participate Not applicable.

All authors approved the final version of the manuscript and agree for publication.